Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Boston Beer Company, Inc.

39.8% sales growth and 21.12% return on equity

The Boston Beer Company, Inc. produces and sells alcohol beverages primarily in the United States.

Boston Beer Company, Inc.’s sales growth this year is expected to be 38.7% and 37.2% for next year.

Year-on-year quarterly revenue growth grew by 30.2%, now sitting on 1.58B for the twelve trailing months.

Boston Beer Company, Inc.’s sales growth for the next quarter is 39.8%. The company’s growth estimates for the ongoing quarter and the next is 98.5% and 82.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.12%.

Volatility

Boston Beer Company, Inc.’s last day, last week, and last month’s average volatility was a positive 0.52%, a positive 0.09%, and a negative 0.19%, respectively.

Boston Beer Company, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 2.11%, 2.45%, and 3.49%, respectively.

Boston Beer Company, Inc.’s Stock Yearly Top and Bottom Value

Boston Beer Company, Inc.’s stock is valued at $919.28 at 19:22 EST, way under its 52-week high of $1,092.80 and way above its 52-week low of $290.02.

Boston Beer Company, Inc.’s Moving Average

Boston Beer Company, Inc.’s value is under its 50-day moving average of $956.05 and above its 200-day moving average of $885.45.

2. First Foundation Inc.

14.1% sales growth and 12.04% return on equity

First Foundation Inc., through its subsidiaries, provides financial services to individuals, businesses, and other organizations in the United States.

First Foundation Inc.’s sales growth this year is anticipated to be 17.6% and 2.6% for next year.

Year-on-year quarterly revenue growth grew by 29.4%, now sitting on 234.63M for the twelve trailing months.

First Foundation Inc.’s sales growth for the next quarter is 14.1%. The company’s growth estimates for the present quarter and the next is 29.4% and 41.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.04%.

Volatility

First Foundation Inc.’s last day, last week, and last month’s average volatility was a negative 3.22%, a positive 0.82%, and a positive 0.44%, respectively.

First Foundation Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 4.89%, 4.35%, and 3.43%, respectively.

First Foundation Inc.’s Stock Yearly Top and Bottom Value

First Foundation Inc.’s stock is valued at $20.82 at 19:22 EST, below its 52-week high of $22.11 and way above its 52-week low of $8.01.

First Foundation Inc.’s Moving Average

First Foundation Inc.’s value is higher than its 50-day moving average of $19.51 and way higher than its 200-day moving average of $16.25.

3. Alexion Pharmaceuticals, Inc.

9.5% sales growth and 8.92% return on equity

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products.

Alexion Pharmaceuticals, Inc.’s sales growth this year is anticipated to be 20.8% and 9.2% for next year.

Year-on-year quarterly revenue growth grew by 25.8%, now sitting on 5.86B for the twelve trailing months.

Alexion Pharmaceuticals, Inc.’s sales growth for the next quarter is 9.5%. The company’s growth estimates for the ongoing quarter and the next is a negative 5.5% and negative -3.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.92%.

Volatility

Alexion Pharmaceuticals, Inc.’s last day, last week, and last month’s average volatility was 1.03%, 0.14%, and 1.49%, respectively.

Alexion Pharmaceuticals, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 0.85%, 1.22%, and 1.47%, respectively.

Alexion Pharmaceuticals, Inc.’s Stock Yearly Top and Bottom Value

Alexion Pharmaceuticals, Inc.’s stock is valued at $157.35 at 19:22 EST, under its 52-week high of $160.03 and way above its 52-week low of $72.67.

Alexion Pharmaceuticals, Inc.’s Moving Average

Alexion Pharmaceuticals, Inc.’s value is way higher than its 50-day moving average of $140.79 and way above its 200-day moving average of $119.39.

4. Simpson Manufacturing Company, Inc.

7.4% sales growth and 20.18% return on equity

Simpson Manufacturing Co., Inc., through its subsidiaries, designs, engineers, manufactures, and sells wood and concrete building construction products.

Simpson Manufacturing Company, Inc.’s sales growth this year is anticipated to be 10% and 5.1% for next year.

Year-on-year quarterly revenue growth grew by 17.5%, now sitting on 1.24B for the twelve trailing months.

Simpson Manufacturing Company, Inc.’s sales growth for the next quarter is 7.4%. The company’s growth estimates for the ongoing quarter and the next is 4.8% and 7.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.18%.

Volatility

Simpson Manufacturing Company, Inc.’s last day, last week, and last month’s average volatility was 1.85%, 0.38%, and 0.54%, respectively.

Simpson Manufacturing Company, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 2.88%, 2.27%, and 2.33%, respectively.

Simpson Manufacturing Company, Inc.’s Stock Yearly Top and Bottom Value

Simpson Manufacturing Company, Inc.’s stock is valued at $102.76 at 19:22 EST, below its 52-week high of $105.89 and way above its 52-week low of $47.02.

Simpson Manufacturing Company, Inc.’s Moving Average

Simpson Manufacturing Company, Inc.’s worth is above its 50-day moving average of $94.69 and above its 200-day moving average of $94.56.

5. Advanced Energy Industries, Inc.

11% sales growth and 14.52% return on equity

Advanced Energy Industries, Inc. designs, manufactures, sells, and supports precision power conversion, measurement, and control solutions worldwide.

Advanced Energy Industries, Inc.’s sales growth this year is anticipated to be 78.7% and 5.9% for next year.

Year-on-year quarterly revenue growth grew by 122.4%, now sitting on 1.38B for the twelve trailing months.

Advanced Energy Industries, Inc.’s sales growth for the next quarter is 11%. The company’s growth estimates for the current quarter and the next is 54% and 26.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.52%.

Volatility

Advanced Energy Industries, Inc.’s last day, last week, and last month’s average volatility was 0.65%, 2.99%, and 0.45%, respectively.

Advanced Energy Industries, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 4.04%, 4.92%, and 3.66%, respectively.

Advanced Energy Industries, Inc.’s Stock Yearly Top and Bottom Value

Advanced Energy Industries, Inc.’s stock is valued at $112.26 at 19:22 EST, under its 52-week high of $115.07 and way higher than its 52-week low of $33.38.

Advanced Energy Industries, Inc.’s Moving Average

Advanced Energy Industries, Inc.’s worth is way above its 50-day moving average of $99.47 and way above its 200-day moving average of $78.07.

6. Thermo Fisher Scientific Inc

32.7% sales growth and 15.95% return on equity

Thermo Fisher Scientific Inc. provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide.

Thermo Fisher Scientific Inc’s sales growth this year is anticipated to be 21.2% and 8.4% for next year.

Year-on-year quarterly revenue growth grew by 35.9%, now sitting on 28.5B for the twelve trailing months.

Thermo Fisher Scientific Inc’s sales growth for the next quarter is 32.7%. The company’s growth estimates for the current quarter and the next is 81.4% and 74.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.95%.

Volatility

Thermo Fisher Scientific Inc’s last day, last week, and last month’s average volatility was 2.39%, 1.93%, and 0.37%, respectively.

Thermo Fisher Scientific Inc’s last day, last week, and last month’s high and low average amplitude percentage was 3.17%, 3.31%, and 2.30%, respectively.

Thermo Fisher Scientific Inc’s Stock Yearly Top and Bottom Value

Thermo Fisher Scientific Inc’s stock is valued at $512.30 at 19:22 EST, below its 52-week high of $532.57 and way higher than its 52-week low of $250.21.

Thermo Fisher Scientific Inc’s Moving Average

Thermo Fisher Scientific Inc’s worth is higher than its 50-day moving average of $467.40 and way above its 200-day moving average of $438.97.

7. Blueprint Medicines Corporation

407.9% sales growth and 36.29% return on equity

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy.

Blueprint Medicines Corporation’s sales growth this year is anticipated to be 1084% and a negative 80.7% for next year.

Year-on-year quarterly revenue growth grew by 8053.2%, now sitting on 811.16M for the twelve trailing months.

Blueprint Medicines Corporation’s sales growth for the next quarter is 407.9%. The company’s growth estimates for the current quarter and the next is a negative 20.7% and 21.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 36.29%.

Volatility

Blueprint Medicines Corporation’s last day, last week, and last month’s average volatility was a positive 0.21%, a positive 0.96%, and a negative 0.28%, respectively.

Blueprint Medicines Corporation’s last day, last week, and last month’s high and low average amplitude percentage was 4.76%, 5.72%, and 4.42%, respectively.

Blueprint Medicines Corporation’s Stock Yearly Top and Bottom Value

Blueprint Medicines Corporation’s stock is valued at $107.22 at 19:22 EST, way below its 52-week high of $125.61 and way higher than its 52-week low of $43.29.

Blueprint Medicines Corporation’s Moving Average

Blueprint Medicines Corporation’s worth is under its 50-day moving average of $111.64 and way higher than its 200-day moving average of $91.74.

8. Helen of Troy Limited

29% sales growth and 19.27% return on equity

Helen of Troy Limited designs, develops, imports, markets, and distributes a portfolio of consumer products worldwide.

Helen of Troy Limited’s sales growth this year is anticipated to be 22.4% and a negative 1.9% for next year.

Year-on-year quarterly revenue growth grew by 34.3%, now sitting on 2.03B for the twelve trailing months.

Helen of Troy Limited’s sales growth for the next quarter is 29%. The company’s growth estimates for the ongoing quarter and the next is a negative 10.6% and 2.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.27%.

Volatility

Helen of Troy Limited’s last day, last week, and last month’s average volatility was a negative 4.40%, a negative 0.75%, and a negative 0.00%, respectively.

Helen of Troy Limited’s last day, last week, and last month’s high and low average amplitude percentage was 6.79%, 5.31%, and 3.23%, respectively.

Helen of Troy Limited’s Stock Yearly Top and Bottom Value

Helen of Troy Limited’s stock is valued at $214.10 at 19:22 EST, under its 52-week high of $230.56 and way higher than its 52-week low of $104.02.

Helen of Troy Limited’s Moving Average

Helen of Troy Limited’s worth is below its 50-day moving average of $216.29 and above its 200-day moving average of $202.50.

LEAVE A REPLY

Please enter your comment!
Please enter your name here